Eli Lilly’s revenue
Eli Lilly and Company (LLY) surpassed Wall Street analysts’ estimates in the second quarter, reporting a 9% YoY (year-over-year) rise in revenue to ~$6.4 billion compared to $5.8 billion in the second quarter of 2017.
The graph above compares the quarterly revenues of Eli Lilly since the first quarter of 2017.
Eli Lilly’s top line increased 9% to ~$6.36 billion in the second quarter driven by a 7% rise in volumes and a 2% favorable impact of foreign exchange. Its adjusted net income rose ~33% YoY to ~$2.9 billion in the second quarter.
US markets contributed nearly 50.7% of Eli Lilly’s total revenue in the second quarter. US markets reported an 11% rise in YoY sales to ~$3.2 billion in the quarter compared to its sales for the second quarter of 2017. The growth in the company’s US revenue was driven by strong sales of its new pharmaceutical products, including Taltz, Basaglar, Trulicity, and Verzenio, as well as an increase in US collaboration revenue. Its revenue growth was partially offset by lower sales of products such as Effient and Strattera during the quarter.
International markets reported a 10% YoY rise in sales to ~$2.8 billion in the second quarter. The growth in the company’s revenue in international markets was driven by the strong sales of its new pharmaceutical products, including Taltz, Olumiant, and Trulicity, and the favorable impact of foreign exchange.